Clinicopathological characteristics according to serum EBV positivity.
Variables | EBV-negative (%) | EBV-positive (%) | |
---|---|---|---|
N | 184 | 79 | |
Age, median years (range) | 59.6 (19–81) | 62.5 (18–87) | 0.090 |
Sex | 0.176 | ||
Male | 97 (52.7) | 44 (55.7) | |
Female | 87 (47.3) | 35 (44.3) | |
Diagnosis | 0.003 | ||
B cell lineage lymphomas | 157 (85.3) | 54 (68.4) | |
T-cell lineage lymphomas | 27 (14.7) | 25 (31.6) | |
Ann Arbor staging | 0.008 | ||
I | 32 (17.4) | 9 (11.4) | |
II | 52 (28.3) | 10 (12.7) | |
III | 44 (23.9) | 30 (38.0) | |
IV | 56 (30.4) | 30 (38.0) | |
Prognostic risk groupa) | 0.005 | ||
Low risk | 79 (42.9) | 18 (22.8) | |
Low-intermediate risk | 40 (21.7) | 31 (39.2) | |
High-intermediate risk | 44 (23.9) | 18 (22.8) | |
High risk | 21 (11.4) | 12 (15.2) | |
Relapse/refractory | 39 (21.2) | 27 (34.2) | 0.038 |
Death | 36 (19.6) | 29 (36.7) | 0.005 |
a)The International Prognostic Index (IPI) was used for non-Hodgkin lymphoma. The International Prognostic Score (IPS) was adjusted for patients with Hodgkin lymphoma, and IPS 0 and 1 were classified as low risk, 2 as low-intermediate, 3 as high-intermediate, and ≥4 as high-risk group in this analysis.
Abbreviation: EBV, Epstein–Barr virus.